Early Cryoprecipitate in Trauma
Start Date: Early 2018
End Date: July 2020
This study will look at the effects of transfusing early high dose
cryoprecipitate (which is a concentrated source of fibrinogen), to
adult trauma patients with severe bleeding within 90 minutes of
admission to hospital.
- This study will evaluate whether early cryoprecipitate reduces death rates when major bleeding occurs after injury.
- This study will investigate the effects of early fibrinogen supplementation in the form of 3 pools (15 units – 6g fibrinogen) of cryoprecipitate on 28 day mortality
- This is a randomised, unblinded, parallel group, controlled, multi-centre trial.
- Inclusion criteria
- The participant is judged to be an adult (16 years or older ) and has sustained severe traumatic injury
- The participant is deemed by the attending clinician to have on-going active haemorrhage
- AND REQUIRES Activation of the local major haemorrhage protocol for management of severe blood loss
- AND HAS STARTED or HAS RECEIVED At least one unit of any blood component
- Participant Exclusion Criteria
- A patient will not be eligible for this trial if they fulfil one or more of the following criteria:
- The participant has been transferred from another hospital
- The trauma team leader deems the injuries incompatible with life
- The trauma team leader deems the patient inappropriate for the trial
- More than 3 hours have elapsed from the time of injury (taken as time of the 999 call if unknown by medical team).